Drug diversion

Wolters Kluwer experts explore Clinical GenAI and analytics solutions at HIMSS24

Retrieved on: 
Tuesday, March 5, 2024
Technology, Health, Finance, Accounting, Pharmaceutical, Professional Services, Artificial Intelligence, Practice Management, Mental Health, Software, Managed Care, Health Technology, Fintech, Clinical Trials, PCP, Wolters Kluwer, Mental health, Exhibition, Health informatics, Global health, FACP, Safety, Health care, University, University of California, Patient, Drug diversion, Infection, UpToDate, Artificial intelligence, Nursing

Experts from Wolters Kluwer Health will be at HIMSS24 leading discussions on how advanced, integrated healthcare innovations are helping healthcare organizations deliver the best patient care around the world.

Key Points: 
  • Experts from Wolters Kluwer Health will be at HIMSS24 leading discussions on how advanced, integrated healthcare innovations are helping healthcare organizations deliver the best patient care around the world.
  • Visitors to booth #2927 will see demonstrations of how Wolters Kluwer Health is helping healthcare organizations drive better outcomes in healthcare through market leading clinical decision support, patient engagement, and drug referential solutions.
  • Learn how UpToDate’s approach to Clinical GenAI prioritizes quality, safety, and transparency with AI Labs.
  • Clinical GenAI can help improve and streamline clinical decision making at the point of care, reduce clinician burnout, and support healthcare organizations to help them deliver better patient outcomes and quality performance.

BioConnect Acquires Silent Partner Technologies to Expand Offerings for Intelligent Asset Tracking and Inventory Management to Bring Security and Accountability to Critical Assets Ranging From Controlled Narcotics to First Responder Gear

Retrieved on: 
Wednesday, January 10, 2024
Hardware, IOT (Internet of Things), Security, Data Management, Consumer Electronics, Technology, Law Enforcement, Emergency Services, Apps, Applications, Biometrics, Public Policy, Government, Other Technology, Software, Networks, Internet, Health, Mobile, Wireless, Fire, SPT, Acquisition, EMS, Drug diversion, Video game

Portfolios of both companies complement each other perfectly.

Key Points: 
  • Portfolios of both companies complement each other perfectly.
  • “Bringing security and accountability to assets ranging from Narcotics and Controlled Goods to First Responder Gear and IT assets is becoming increasingly critical in today’s environment and in particular eliminating Drug Diversion feeding the Opioid crisis.
  • With the acquisition of Silent Partner Technologies, together we will offer a simple cloud subscription to upgrade any area protecting assets to become the next generation ‘Smart Space’ solution.
  • Customers looking for higher security and ‘chain of custody’ accountability to protect their critical assets will find this solution very compelling,” commented Rob Douglas, Founder and CEO of BioConnect.

Artificial Intelligence-Powered Drug Diversion Surveillance Now Part of Wolters Kluwer’s Sentri7 Suite

Retrieved on: 
Thursday, November 30, 2023
Software, Practice Management, Pharmaceutical, Health, Data Management, Hospitals, Health Technology, Technology, Public health surveillance, Safety, Antimicrobial stewardship, Pharmacist, Wolters Kluwer, Machine learning, Hospital, Drug diversion, AI, Nursing, Medical device, Pharmaceutical industry

To better equip healthcare facilities to address this growing threat to patient and staff safety, Wolters Kluwer Health is expanding its Sentri7® clinical surveillance suite to include the Sentri7 Drug Diversion solution, formerly Flowlytics® from Invistics.1

Key Points: 
  • To better equip healthcare facilities to address this growing threat to patient and staff safety, Wolters Kluwer Health is expanding its Sentri7® clinical surveillance suite to include the Sentri7 Drug Diversion solution, formerly Flowlytics® from Invistics.1
    Despite an increasing number of solutions available on the market to address drug diversion, healthcare executives’ confidence remains low.
  • The 2023 State of Drug Diversion Survey found only 40% of executives are very confident in the efficacy of their drug diversion detection programs.
  • Powered by AI and machine learning, the Sentri7 Drug Diversion solution aims to address these gaps in confidence with a proven track record of proactive drug diversion surveillance that minimizes the burden on hospital staff.
  • “Using the Sentri7 Drug Diversion solution, my team is in a better position to be proactive in our drug diversion surveillance, ultimately supporting heightened safety across our organization.

Wolters Kluwer’s drug diversion solution receives outstanding rating in AI/ML effectiveness by KLAS

Retrieved on: 
Wednesday, August 30, 2023
Technology, Hospitals, Law Enforcement, Emergency Services, Clinical Trials, Health Technology, Public Policy, Government, Software, Pharmaceutical, Health, Artificial Intelligence, Learning, Optimism, Wolters Kluwer, Research, KLAS, Quality, Sale, Plasma protein binding, Student, Hospital, Acquisition, Patient, Patient safety, Risk, Artificial intelligence, AI, Drug diversion, Medical device, Pharmaceutical industry, Nursing

Wolters Kluwer Health is proud to announce that following its acquisition of Invistics , the company’s drug diversion monitoring software received exceptional recognition from KLAS in the Drug Diversion Monitoring 2023 report.

Key Points: 
  • Wolters Kluwer Health is proud to announce that following its acquisition of Invistics , the company’s drug diversion monitoring software received exceptional recognition from KLAS in the Drug Diversion Monitoring 2023 report.
  • The recently published KLAS report highlights the artificial intelligence (AI) capabilities, customer satisfaction, ease of use, and effectiveness of the solution in identifying and preventing drug diversion incidents within healthcare organizations.
  • The KLAS report underscored the significance of the drug diversion challenge and the vital role that Wolters Kluwer's new drug diversion solution plays in addressing it.
  • The division of Wolters Kluwer supports clinical effectiveness, learning and research, clinical surveillance and compliance, and data solutions.

New Report Finds Travel Nurses at the Center of an Alarming Drug Diversion Trend

Retrieved on: 
Tuesday, June 28, 2022
Artificial intelligence, Patient, Heart, CEO, Technology, Forbes, GLOBE, Drug diversion, Modern Healthcare, American City Business Journals, The Baltimore Sun, Risk, Nursing, American, Organization, The Last Best Place, Entrepreneurship, Machine learning, Safety, Hospital, Health insurance, Pharmaceutical industry, Medicine, Health care

The report, The State of Drug Diversion in America , covers an alarming drug diversion trend which surfaced in the first half of 2022, a look ahead at what the healthcare industry can expect in 2022 and beyond, technology's impact on drug diversion surveillance, and key elements for an optimal drug diversion prevention program.

Key Points: 
  • The report, The State of Drug Diversion in America , covers an alarming drug diversion trend which surfaced in the first half of 2022, a look ahead at what the healthcare industry can expect in 2022 and beyond, technology's impact on drug diversion surveillance, and key elements for an optimal drug diversion prevention program.
  • So far in 2022, there has been an upward trend in contract staff, or travel nurses, diverting drugs across multiple states.
  • According to the report, technology has shown to be a vital tool in the fight against drug diversion.
  • Advanced analytics and machine learning can also detect drug diversion faster, helping to stem the damage and mitigate risk.

BIGG Digital Assets Inc. Provides Corporate Update on Blockchain Intelligence Group

Retrieved on: 
Thursday, January 20, 2022
Bitcoin, Yoy, National Association, Conference, SOV, ATII, Defence Strategic Policy and Intelligence Group, KYC, Organization, Growth, GLOBE, VASP, NFT, Singapore FinTech Festival, Marketing, Law enforcement, USD, CSE, International Association, Lists of crime films, Industry, Compliance, Drug diversion, Awareness, Cryptocurrency, Human voice

VANCOUVER, British Columbia, Jan. 20, 2022 (GLOBE NEWSWIRE) -- BIGG Digital Assets Inc. ("BIGG" or the "Company")(CSE: BIGG; OTCQX: BBKCF; WKN: A2PS9W), owner of Blockchain Intelligence Group ( blockchaingroup.io ), a cryptocurrency compliance and intelligence company, is pleased to provide a full corporate update on the business and 2022 outlook.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 20, 2022 (GLOBE NEWSWIRE) -- BIGG Digital Assets Inc. ("BIGG" or the "Company")(CSE: BIGG; OTCQX: BBKCF; WKN: A2PS9W), owner of Blockchain Intelligence Group ( blockchaingroup.io ), a cryptocurrency compliance and intelligence company, is pleased to provide a full corporate update on the business and 2022 outlook.
  • In Q4 2021, Blockchain Intelligence Group recorded gross operating revenue of approximately $466,000, with 72% from software sales, 27% from training, and 1% from forensic consulting.
  • Blockchain Intelligence Group is well-positioned to expand its customer base and grow its revenue through 2022.
  • Blockchain Intelligence Group is the third most recognized blockchain analytics company globally by Share of Voice (SoV).

SCRIPPS SAFE’S CHRISTOPHER VON ZWEHL HONORED WITH NATIONAL ASSOCIATION OF STATE CONTROLLED SUBSTANCES AUTHORITIES 2021 PRESIDENT’S AWARD

Retrieved on: 
Tuesday, December 21, 2021
Advisory board, Policy, GLOBE, Hospital, Health care, National security, Timeline of cannabis laws in the United States, Education, International Association, FBI, Public health, National Association, Nursing, Transport, Society, Narcotic, APPA, Safety, Veterinarian, National, Solution, Pharmacy, Software as a service, Senior, Drug diversion, EMS, Pharmaceutical industry

Naples, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Scripps Safe, Inc., a national leader in narcotics transportation, storage and dispensing solutions, announced that Senior Vice President Christopher von Zwehl is the recipient of the National Association of State Controlled Substances Authorities (NASCSA) 2021 Presidents Award.

Key Points: 
  • Naples, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Scripps Safe, Inc., a national leader in narcotics transportation, storage and dispensing solutions, announced that Senior Vice President Christopher von Zwehl is the recipient of the National Association of State Controlled Substances Authorities (NASCSA) 2021 Presidents Award.
  • We are pleased to recognize Chris von Zwehls contribution to our organization, said Joe Fontenot, NASCSAs chairman and former president.
  • Christopher von Zwehl is very active in the industries where Scripps Safe participates.
  • Scripps Safe is a member of the FBI's InfraGard Partnership of Protection, and all staff members maintain National Security clearance.

Guidepost Solutions Welcomes Russell Holske, Drug Enforcement Administration Leader and Pharmaceutical Investigations Chief

Retrieved on: 
Wednesday, August 4, 2021
Other Policy Issues, Medical Supplies, General Health, Homeland Security, Congressional News, Views, Public Policy, Government, Pharmaceutical, Courts, Other Professional Services, Law Enforcement, Emergency Services, Legal, Medical Devices, Healthcare Reform, Finance, Consulting, Banking, Accounting, Professional Services, Health, White House, Federal Government, State, Local, Drug control law, Drug diversion, Illegal drug trade, Medical law, United States criminal law

Guidepost Solutions , a global leader in compliance, investigations, monitoring, and security consulting, announced the appointment of Russell C. Holske, Jr. as a senior managing director in its Washington, D.C. office.

Key Points: 
  • Guidepost Solutions , a global leader in compliance, investigations, monitoring, and security consulting, announced the appointment of Russell C. Holske, Jr. as a senior managing director in its Washington, D.C. office.
  • Holske, an experienced leader in global investigations, including pharmaceutical diversion, will support the companys global investigations and controlled substances compliance practices.
  • Holske had a distinguished career of over 30 years with the Drug Enforcement Administration, overseeing global investigations and including multiple leadership positions in the United States, Asia Pacific, and Europe.
  • Guidepost Solutions offers global investigations, compliance, monitoring, and security and technology consulting solutions that keep you moving forward.

IntelliGuard Hosts Webinar with Top Anesthesiologist Dr. Jodi Kuhlman on the Dangers and Consequences of Drug Diversion

Retrieved on: 
Thursday, June 24, 2021
Opioids, Psychoactive drugs, Drugs, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Drug control law, Fentanyl, Sufentanil, Drug diversion, Heroin

As one of the top anesthesiologists in the country, Dr. Jodi Kuhlman fell victim to drug diversion, becoming addicted to sufentanil and fentanyl.

Key Points: 
  • As one of the top anesthesiologists in the country, Dr. Jodi Kuhlman fell victim to drug diversion, becoming addicted to sufentanil and fentanyl.
  • Drug diversion the act of stealing controlled substances for personal or illicit use is unfortunately a prevalent issue among healthcare systems of all sizes.
  • And if convicted, drug diversion is a criminal offense that could lead to the loss of a medical license .
  • Like myself, it is not uncommon to succumb to those pressures and fall victim to addiction," said Jodi Kuhlman, M.D.

Kit Check Launches Kit Check Professional Services to Offer Hospitals Hands-On Support for Drug Diversion Programs

Retrieved on: 
Wednesday, June 23, 2021
Technology, Nursing, Hospitals, Consulting, Professional services, Software, Health, Pharmaceutical, Data management, Articles, Courts, Crime prevention, Criminal law, Diversion program, Punishment, Diversion, Drug diversion, Patient safety, Law, Justice

Kit Check , the leading automation vendor in Medication Intelligence solutions that brings cost savings, efficiency, and patient safety to hospitals, today announced the launch of Kit Check Professional Services (KCPS) to help support hospitals in need of a hands-on approach to daily activities involved with their drug diversion program.

Key Points: 
  • Kit Check , the leading automation vendor in Medication Intelligence solutions that brings cost savings, efficiency, and patient safety to hospitals, today announced the launch of Kit Check Professional Services (KCPS) to help support hospitals in need of a hands-on approach to daily activities involved with their drug diversion program.
  • These offerings help hospitals busy trying to run various programs ensure their drug diversion management is thoroughly overseen and enables them to identify any potential anomalies.
  • At Kit Check, we understand that hospitals are trying to manage a wide variety of tasks, including drug diversion prevention, said Jennifer Symon, R.Ph., MBA, FACHE, director of clinical solutions at Kit Check.
  • Kit Check Professional Services can help augment a hospitals program and enable staff to devote time to other pressing tasks.